FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890897881> ?p ?o ?g. }

• W2890897881 endingPage "322" @default.
• W2890897881 startingPage "315" @default.
• W2890897881 abstract "Overexpression and cellular mis-localization of aurora kinase A (AURKA) in gastrointestinal cancers results in chromosomal instability, activation of multiple oncogenic pathways, and inhibition of pro-apoptotic signaling. Inhibition of AURKA causes mitotic delays, severe chromosome congression, and activation of p53/p73 leading to cell death. Our preclinical data showed cooperative activity with the AURKA inhibitor alisertib and platinum agents in cell lines and xenografts, and suggested an optimal treatment window. Therefore, this study was designed to determine the maximum-tolerated dose (MTD) of alisertib in combination with modified FOLFOX (mFOLFOX), as this is a standard platinum-based therapy for gastrointestinal cancers. Standard 3 + 3 dose escalation was used, where the starting dose of alisertib was 10 mg twice daily (Days 1–3), with leucovorin (400 mg/m2) and oxaliplatin (85 mg/m2) on Day 2 followed by continuous 46-h 5-FU (2400 mg/m2) infusion on Days 2–4 in 14-day cycles. Fourteen patients with advanced gastrointestinal cancers were enrolled and two doses explored; two patients were not evaluable for dose-limiting toxicity (DLT) and replaced. Two patients experienced DLTs at 20 mg of alisertib (Grade 3 fatigue (n = 2); Grade 3 nausea, vomiting, dehydration with hospitalization (n = 1)). MTD was 10 mg alisertib with 85 mg/m2 oxaliplatin and 2400 mg/m2 5-FU. Most frequent toxicities were nausea (57%), diarrhea, fatigue, neuropathy, and vomiting (43%), and anorexia and anemia (36%); most were Grade 1–2. One patient with colorectal cancer had a partial response of 12 evaluable patients, and four patients had stable disease. Alisertib in combination with mFOLFOX did not demonstrate unexpected side effects, but the regimen was only tolerable at the lowest dose investigated." @default.
• W2890897881 created "2018-09-27" @default.
• W2890897881 creator A5001099941 @default.
• W2890897881 creator A5004542056 @default.
• W2890897881 creator A5012787104 @default.
• W2890897881 creator A5015750678 @default.
• W2890897881 creator A5017967471 @default.
• W2890897881 creator A5039492614 @default.
• W2890897881 creator A5047032605 @default.
• W2890897881 creator A5048600723 @default.
• W2890897881 creator A5060219345 @default.
• W2890897881 creator A5064953304 @default.
• W2890897881 creator A5073593424 @default.
• W2890897881 creator A5075392197 @default.
• W2890897881 creator A5088976086 @default.
• W2890897881 date "2018-09-06" @default.
• W2890897881 modified "2023-10-18" @default.
• W2890897881 title "Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer" @default.
• W2890897881 cites W1657157395 @default.
• W2890897881 cites W1970815499 @default.
• W2890897881 cites W1971796809 @default.
• W2890897881 cites W1980612591 @default.
• W2890897881 cites W1981073960 @default.
• W2890897881 cites W1981427365 @default.
• W2890897881 cites W1996506613 @default.
• W2890897881 cites W1997353566 @default.
• W2890897881 cites W2002173586 @default.
• W2890897881 cites W2006113261 @default.
• W2890897881 cites W2016015994 @default.
• W2890897881 cites W2031667278 @default.
• W2890897881 cites W2031805729 @default.
• W2890897881 cites W2038619046 @default.
• W2890897881 cites W2062364825 @default.
• W2890897881 cites W2064261028 @default.
• W2890897881 cites W2069910776 @default.
• W2890897881 cites W2075648742 @default.
• W2890897881 cites W2079788104 @default.
• W2890897881 cites W2090131485 @default.
• W2890897881 cites W2098615262 @default.
• W2890897881 cites W2108541596 @default.
• W2890897881 cites W2116565287 @default.
• W2890897881 cites W2134064448 @default.
• W2890897881 cites W2137151867 @default.
• W2890897881 cites W2137429755 @default.
• W2890897881 cites W2138747235 @default.
• W2890897881 cites W2141396204 @default.
• W2890897881 cites W2144010228 @default.
• W2890897881 cites W2144690940 @default.
• W2890897881 cites W2153081604 @default.
• W2890897881 cites W2159616963 @default.
• W2890897881 cites W2171919275 @default.
• W2890897881 cites W2243179149 @default.
• W2890897881 cites W2274409794 @default.
• W2890897881 cites W2276913308 @default.
• W2890897881 cites W2279017153 @default.
• W2890897881 cites W2397161433 @default.
• W2890897881 cites W2470602494 @default.
• W2890897881 cites W2570618306 @default.
• W2890897881 cites W2587003744 @default.
• W2890897881 cites W2587137240 @default.
• W2890897881 doi "https://doi.org/10.1007/s10637-018-0663-0" @default.
• W2890897881 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6401337" @default.
• W2890897881 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30191522" @default.
• W2890897881 hasPublicationYear "2018" @default.
• W2890897881 type Work @default.
• W2890897881 sameAs 2890897881 @default.
• W2890897881 citedByCount "10" @default.
• W2890897881 countsByYear W28908978812020 @default.
• W2890897881 countsByYear W28908978812021 @default.
• W2890897881 countsByYear W28908978812022 @default.
• W2890897881 countsByYear W28908978812023 @default.
• W2890897881 crossrefType "journal-article" @default.
• W2890897881 hasAuthorship W2890897881A5001099941 @default.
• W2890897881 hasAuthorship W2890897881A5004542056 @default.
• W2890897881 hasAuthorship W2890897881A5012787104 @default.
• W2890897881 hasAuthorship W2890897881A5015750678 @default.
• W2890897881 hasAuthorship W2890897881A5017967471 @default.
• W2890897881 hasAuthorship W2890897881A5039492614 @default.
• W2890897881 hasAuthorship W2890897881A5047032605 @default.
• W2890897881 hasAuthorship W2890897881A5048600723 @default.
• W2890897881 hasAuthorship W2890897881A5060219345 @default.
• W2890897881 hasAuthorship W2890897881A5064953304 @default.
• W2890897881 hasAuthorship W2890897881A5073593424 @default.
• W2890897881 hasAuthorship W2890897881A5075392197 @default.
• W2890897881 hasAuthorship W2890897881A5088976086 @default.
• W2890897881 hasBestOaLocation W28908978812 @default.
• W2890897881 hasConcept C121608353 @default.
• W2890897881 hasConcept C126322002 @default.
• W2890897881 hasConcept C143998085 @default.
• W2890897881 hasConcept C2776694085 @default.
• W2890897881 hasConcept C2778260052 @default.
• W2890897881 hasConcept C2778496288 @default.
• W2890897881 hasConcept C2780580376 @default.
• W2890897881 hasConcept C2780852908 @default.
• W2890897881 hasConcept C2780962732 @default.
• W2890897881 hasConcept C526805850 @default.
• W2890897881 hasConcept C71924100 @default.
• W2890897881 hasConcept C90924648 @default.

• next